A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to determine whether LCQ908 is effective and safe in lowering triglycerides in subjects with Familial Chylomicronemia Syndrome (FCS) (Hyperlipoproteinemia [HLP] type I). Data from this study will be used to support a registration submission of LCQ908 20 mg and 40 mg as treatment of chylomicronemia in subjects with FCS (HLP Type 1).

Condition or disease	Intervention/treatment	Phase
Familial Chylomicronemia Syndrome (FCS)	Drug: LCQ908; Drug: Placebo	Phase 3

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	45 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
Study Start Date :	July 2012
Actual Primary Completion Date :	May 2014
Actual Study Completion Date :	May 2014

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: LCQ908 20 mg; In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary.	Drug: LCQ908; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg Drug: Placebo; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Other Name: LCQ908
Experimental: LCQ908 40 mg; In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary.	Drug: LCQ908; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg Drug: Placebo; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Other Name: LCQ908
Placebo Comparator: Placebo; In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary.	Drug: Placebo; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Other Name: LCQ908

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Percent Change in Fasting Triglycerides From Baseline to 12 Weeks [ Time Frame: Baseline to 12 weeks ]
   Blood samples were collected for a fasting lipid panel, including triglycerides. If the 12-week value was missing, the measurement value at 12 weeks or the last available post-baseline measurement value during the double-blind treatment period was analyzed. Baseline is defined as the average of fasting triglyceride values taken at day -3 and day 1. Adjusted geometric means are calculated by back-transforming the adjusted means from the model and expressing as a percentage change from baseline.

Secondary Outcome Measures :

1. Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL) [ Time Frame: Baseline, 12 weeks, 24 weeks, 52 weeks ]
   Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.
2. Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL) [ Time Frame: 12 weeks, 24 weeks, 52 weeks ]
   Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.
3. Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline [ Time Frame: Baseline, 12 weeks, 24 weeks, 52 weeks ]
   Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.
4. Percentage of Patients Achieving Fasting Triglycerides (TG) Target Thresholds [ Time Frame: 12 weeks, 24 weeks, 52 weeks ]
   Percentage of patients reaching target values of <1000 mg/dL or target values of < 2000 mg/dL for fasting triglycerides is reported. Pecentage calculated as (m/n)*100; where 'm' The number of patients who reach target values for fasting triglyceride, 'n' the number of patients with non-missing fasting triglyceride.
5. Percent Change From Baseline in Fasting Triglycerides [ Time Frame: Baseline, 24 weeks, 52 weeks ]
6. Percent Change From Baseline for Postprandial Triglycerides Following the Standardized Meal Tolerance Test at Week 12 [ Time Frame: 0-24 hours at Baseline, Week 12 ]
   Post prandial peak triglycerides - maximum triglyceride value over 0-24 hours Post prandial triglycerides AUC0-24 - area under the time curve for triglycerides over 0-24 Adjusted geometric means are calculated by back-transforming the adjusted means from the model and expressed as a percentage change from baseline. hours
7. Pharmacokinetics of LCQ908 - Trough Concentration (Cmin) and Observed Maximum Blood Concentration (Cmax) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]
   Lowest observed blood concentration (Cmin) and observed maximum blood concentration (Cmax) following drug administration derived from non-compartmental analysis using scheduled sampling time for the whole dataset.
8. Pharmacokinetics of LCQ908- Area Under the Plasma Concentration Time Curve AUC (0-24hour) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]
   The area under the concentration-time curve from time zero to 24 hours after drug administration was calculated by using linear trapezoidal rule.
9. Pharmacokinetics of LCQ908- Time to Reach Maximum Concentration Following Drug Administration Tmax (Hours) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]
10. Pharmacokinetics of LCQ908- Average Observed Blood Concentration (Cavg) [ Time Frame: 0, 1, 2, 3, 4, 6, and 24 hours at Week 12 ]
    Average observed blood concentration measured by (AUC0-24)/24.
11. Number of Patients Reported With Any Adverse Event, Serious Adverse Event and Death [ Time Frame: 52 weeks ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Key Inclusion Criteria:

1. Written informed consent given before any assessment was performed for Period I.
2. Male and female patients ages at least 18 years of age.
3. Fasting triglyceride ≥ 8.4 mmol/L (750 mg/dL) at Screening.

4. An established diagnosis of FCS (HLP Type I) confirmed through ultracentrifugation or by documented medical history of a fasting triglyceride ≥ 8.4 mmol/L (750 mg/dL) and by documentation of any of the following at Screening or during the Screening Period:

   • Confirmed homozygote or compound heterozygote for known loss-of-function mutations in Type I-causing genes (such as LPL, apo C II, GPIHBP1, or LMF1)
   • Post heparin plasma LPL activity of ≤ 20% of normal
   • Confirmed presence of LPL inactivating antibodies
5. History of pancreatitis.

Key Exclusion Criteria:

1. Current pancreatitis, pancreatitis was required to be inactive for at least 1 week prior to the screening Visit.
2. Treatment with fish oil preparations within 4 weeks prior to randomization.
3. Treatment with bile acid binding resins (i.e., colesevelam, etc.) within 4 weeks prior to randomization.
4. Treatment with fibrates within 4 weeks prior to randomization.
5. Glybera [alipogene tiparvovec (AAV1-LPLS447X)] gene therapy exposure within the two years prior to screening.
6. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
7. Any surgical or medical conditions, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study or might significantly alter the absorption, distribution, metabolism or excretion of the study drug.
8. History of drug or alcohol abuse within the 12 months prior to randomization or evidence of such abuse at screening.
9. Evidence of liver disease or liver injury as indicated by abnormal liver function tests such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), or serum bilirubin.
10. Estimated glomerular filtration rate (eGFR) <30mL/min/1.73m2 or history of chronic renal disease.
11. Participation in any clinical investigation within four (4) weeks prior to initial dosing or longer if required by local regulations, or any other limitation of participation based on local regulations.
12. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
13. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive HCG laboratory test.
14. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 100 days after discontinuation of investigational study drug.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Washington
Novartis Investigative Site
Seatlle, Washington, United States, 98104
Canada, Quebec
Novartis Investigative Site
Chicoutimi, Quebec, Canada, G7H 7P2
Novartis Investigative Site
Ste-Foy, Quebec, Canada, G1V4M6
Canada
Novartis Investigative Site
Ouest-Montreal, Canada, H2W1R7
France
Novartis Investigative Site
Bron, France, 69677
Novartis Investigative Site
Nantes, France, 44093
Novartis Investigative Site
Paris Cedex 13, France, 75651
Germany
Novartis Investigative Site
Hamburg, Germany, 20246
Novartis Investigative Site
Köln, Germany, 50937
Netherlands
Novartis Investigative Site
Meibergdreef 9, Netherlands, 1105 AZ
South Africa
Novartis Investigative Site
Cape Town, South Africa, 7925
Spain
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41013
United Kingdom
Novartis Investigative Site
Manchester, United Kingdom, M13 9NT

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

Study Director:	Novartis Pharmaceuticals	Novartis Pharmaceuticals

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT01514461 History of Changes
Other Study ID Numbers:	CLCQ908B2302; 2011-005535-68 ( EudraCT Number )
First Posted:	January 23, 2012
Results First Posted:	June 3, 2015
Last Update Posted:	June 3, 2015
Last Verified:	May 2015

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Hyperlipoproteinemia (HLP Type I); Fasting Triglycerides

Additional relevant MeSH terms:

Hyperlipoproteinemia Type I; Syndrome; Disease; Pathologic Processes; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors	Genetic Diseases, Inborn; Hyperlipoproteinemias; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases